Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | PPOX | P50336 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8371717 | 0.81 | P2RX1 (0.46) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7741945 | 0.81 | MPO (0.54) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7608993 | 0.81 | MPO (0.52) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7609217 | 0.81 | MEN1 (0.50) | KMT2AMEN1MPOGRIK1P2RX1 | |
| SCHEMBL27653560 | 0.79 | KCNMA1 (0.42) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL7612259 | 0.78 | LMNA (0.44) | AKR1B1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL6440646 | 0.77 | GRIK1 (0.44) | LMNAMAPTHTTKMT2AMEN1 | |
| SCHEMBL7741946 | 0.77 | KDM4E (0.49) | AKR1C3AKR1C2KMT2AMEN1MPO | |
| SCHEMBL7621277 | 0.77 | MEN1 (0.41) | AKR1C3AKR1C2LMNAKMT2AMEN1 | |
| SCHEMBL7487236 | 0.76 | PLA2G10 (0.43) | MAPTHTTKMT2AMEN1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | NEUROSEARCH A/S (DK) | 2004-04-22 | — | — | US | disclosed |
| US-6417393-B1 | TREATMENT OF SICKLE-CELL ANEMIA, BRAIN EDEMA FROM TUMORS OR ISCHEMIA, DIARRHEA, AND GLAUCOMA; HYPOTENSIVE, WOUND HEALING, ANTIINFLAMMATORY AND ANTIALLERGEN AGENTS | NEUROSEARCH A/S (DK) | 2002-07-09 | — | — | US | disclosed |
| EP-0906273-A1 | PHENYL DERIVATIVES CONTAINING AN ACIDIC GROUP, THEIR PREPARATION AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045400-A1 | PHENYL DERIVATIVES CONTAINING AN ACIDIC GROUP, THEIR PREPARATION AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077634-A1 | Treatment of diseases characterized by excessive or insufficient cell death | APAF1, CASP9, AIFM1 | AKR1B1 1805/4885AKR1C4 3778/4885AKR1C3 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.